world-wide. Antibody-mediated immune responses can offer protection against repeated 2 exposure to S. pneumoniae, yet vaccines only offer partial protection. Patients with 3 Activated PI3Kδ Syndrome (APDS) are highly susceptible to S. pneumoniae. We generated 4 a conditional knockin mouse model of this disease and identified a CD19 + B220 -B cell 5 subset that is induced by PI3Kδ signaling, is resident in the lungs, and which promotes 6 increased susceptibility to S. pneumoniae during the early phase of infection via an 7 antibody-independent mechanism. We show that an inhaled PI3Kδ inhibitor improves 8 survival rates following S. pneumoniae infection in wild-type mice and in mice with 9 activated PI3Kδ. These results suggest that a subset of B cells in the lung can promote the 10 severity of S. pneumoniae infection, representing a novel therapeutic target. 11 100 2B). This pattern resembles results found in patients with APDS 10 . In wild-type and 101 p110δ E1020K-GL cells, the PI3Kδ-selective inhibitor nemiralisib reduced PIP3 to the background 102 level observed in p110δ D910A cells, which, as expected, were insensitive to nemiralisib ( Fig  103  2A, B) . 104 105 PIP3 binds to the protein kinase AKT, supporting its phosphorylation on Thr308 and 106 subsequent activation. Western blotting of purified p110δ E1020K-GL T cells showed increased 107
Introduction 12
Streptococcus pneumoniae is an invasive extracellular bacterial pathogen and is a leading 13 cause of morbidity and mortality. Although S. pneumoniae can cause disease in 14 immunocompetent adults, it commonly colonizes the upper airways without causing 15 disease. The World Health Organization has estimated that there are 14.5 million episodes 16 of severe pneumococcal disease and that 1.6 million people die of pneumococcal disease 17 every year 1 . Despite the implementation of global vaccination programs, S. pneumoniae 18 infection remains a major disease burden 2-4 . 19 20
Invasive S. pneumoniae infection is a major cause of lower airway infections (pneumonia), 21 sepsis and meningitis. Healthy people at the extremes of age are more susceptible to 22 pneumococcal disease, as are people with chronic obstructive pulmonary disease (COPD), 23 however those at greatest risk are patients with splenic dysfunction or immune deficiency. 24 This increased susceptibility results at least in part from the lack of protective antibodies 25 against conserved protein antigens or against polysaccharides that form part of the 26 pneumococcal capsule 5 . Indeed, the protective role of antibodies in pneumococcal disease 27 is most obvious in individuals with congenital (primary) immunodeficiencies (PIDs). This was 28 first recognized in a patient with X-linked agammaglobulinemia (XLA), a syndrome 29 subsequently shown to be caused by a block in B cell development due to loss-of-function 30 mutations in BTK 6-8 . These patients remain highly susceptible to S. pneumoniae into 31
adulthood, but can be effectively treated by the administration of immunoglobulins from 32 healthy donors. 33 34 We and others have recently described cohorts of immune deficient patients with activating 35 mutations in PIK3CD, the gene encoding the p110δ catalytic subunit of phosphoinositide 3-36 kinase δ (PI3Kδ) 9-11 . PI3Kδ is a lipid kinase that catalyzes the phosphorylation of the 37 phosphatidylinositol-(4,5)-bisphosphate lipid to produce phosphatidylinositol-(3,4,5)-38 trisphosphate (PIP3). PI3Kδ is expressed in cells of the immune system and regulates many 39 aspects of immune cell signaling, particularly in lymphocytes 12, 13 . Activated 40 phosphoinositide 3-kinase δ syndrome (APDS) is a combined immunodeficiency affecting T 41 and B cells. APDS patients suffer from recurrent sinopulmonary infections, with S. 42 pneumoniae being the most commonly isolated pathogen 14 . 85% of APDS patients have 43 been diagnosed with pneumonia 15 . APDS patients are also more likely to develop structural 44 lung damage (bronchiectasis) than patients with other PIDs 14 . The mechanism underpinning 45 3 the increased susceptibility to pneumococcal infection in APDS is unclear 12 . Although APDS 46 patients often lack IgG2, the protection afforded by immunoglobulin replacement therapy is 47 not as robust as that observed in patients with pure antibody deficiencies, suggesting that 48 antibody-independent PI3Kδ-driven mechanisms may be involved 14 . The monogenic nature 49 of APDS allows us to dissect mechanisms of susceptibility to S. pneumoniae infection on 50 cellular and molecular levels, and to determine whether PI3Kδ inhibitors may help reduce 51 the susceptibility to S. pneumoniae. If so, PI3Kδ inhibitors, that are in development for the 52 treatment of inflammatory and autoimmune diseases, might also have wider applications to 53 reduce the pathological consequences of S. pneumoniae infection 16 . In this study, we have 54 explored mechanisms by which PI3Kδ hyperactivation drives susceptibility to S. pneumoniae 55 infection. We found that the administration of the PI3Kδ-selective inhibitor nemiralisib 56
(GSK-22696557) 17, 18 reduced the severity of pneumococcal disease in wild-type mice. To 57 investigate this further, we generated a p110δ E1020K mouse model that accurately 58
recapitulates the genetics and immunological phenotype of APDS, and displays increased 59 susceptibility to S. pneumoniae infection. We show that this susceptibility segregates with 60 enhanced PI3Kδ signaling in B cells, which exacerbate S. pneumoniae infection at early time 61 points before the adaptive immune response comes into play. Of note, we have identified a 62 previously unappreciated population of CD19 + B220 -IL-10-secreting cells that was present in 63 wild-type mice but expanded 10-20 fold in p110δ E1020K mice. We demonstrate that 64 nemiralisib reduces the frequency of IL-10-producing B cells in the lung and improves 65 survival of p110δ E1020K mice. Similarly, a higher proportion of transitional B cells from APDS 66 patients produced IL-10 and this was reduced by nemiralisib. This study provides new 67 insights into the pathogenesis of the early stages of invasive S. pneumoniae disease and 68 offers the potential of future therapeutic strategy to alleviate the severity of this disease in 69 susceptible patients. 70
Results

71
Inhaled nemiralisib alleviates the severity of S. pneumoniae infection in mice 72 Given that APDS patients are more susceptible to S. pneumoniae, we sought to determine 73 whether nemiralisib, an inhaled PI3Kδ inhibitor which is in development for the treatment 74 and prevention of COPD excacerbations 17, 18 , would alter susceptibility to airway infections. 75 We treated mice with nemiralisib and then infected them intranasally with S. pneumoniae. 76
Nemiralisib-treated mice showed prolonged survival compared to mice given vehicle control 77 (Fig 1) . This protection was only effective if the drug was administered before and during 78 infection (Fig 1) . By contrast, nemiralisib administration 8h or 24h post infection had no 79 impact on survival of the mice. These data suggest that PI3Kδ modulates the immune 80 response during early S. pneumoniae infection, either by inhibiting protective immunity, or 81 by promoting an adverse response. 82 83
Mouse model of APDS: hyperactive PI3Kδ signaling and altered B and T cell 84 development in p110δ E1020K mice 85 We generated a conditional knock-in mouse harboring mutation E1020K in the Pik3cd gene 86
that is equivalent to the most common APDS-causing mutation E1021K in humans 87
( Supplementary Fig 1) . These mice were subsequently crossed with different Cre-expressing 88 lines to either generate germline mice where p110δ E1020K is expressed in all cells 89 (p110δ E1020K-GL ) or selectively in B cells using Mb1 Cre (p110δ E1020K-B ), in T cells using Cd4 Cre 90 (p110δ E1020K-T ) or myeloid cells using Lyz2 Cre (p110δ E1020K-M ). We studied p110δ E1020K mice in 91 comparison with wild-type and p110δ D910A mice that have catalytically inactive p110δ 19 . 92 93
Initially, we tested if p110δ E1020K mice have increased PI3Kδ activity and display the 94 characteristic immunological phenotype of APDS. Biochemical analyses of B cells and T cells 95 from p110δ E1020K-GL mice confirmed that the kinase is hyperactive (Fig 2) . Measurements of 96 PIP3 in T cells showed that p110δ E1020K is about 6 times as active as the wild-type kinase 97
following stimulation with anti-CD3 and anti-CD28, but with no evidence for increased basal 98 activity (Fig 2A) . In B cells, p110δ E1020K led to increased basal PIP3 levels, but it was further 99 increased only about 2-fold compared to wild-type mice after stimulation with anti-IgM ( Wild-type mice were treated twice daily with the inhaled PI3Kδ inhibitor nemiralisib for the duration of the study: when treatment was started 24h prior to infection with S. pneumoniae, survival rates were improved. When started 8h or 24h post-infection, the treatment had no effect on survival outcome. (-24h: data from 5 independent experiments combined n=60; +8h/+24h: data from 3 independent experiments combined n=36). Germline p110δ E1020K-GL mice had near normal numbers of myeloid cells in the bone marrow 117 and spleen. In the bone marrow we observed a significant B cell lymphopenia that was 118 associated with a block in B cell development between Pro-B and Pre-B cells and did not 119 extend to the spleen. Although these mice had normal numbers of splenic B cells, there was 120 an increased proportion of marginal zone B and B1 cells with an altered distribution of 121 transitional B cells ( Supplementary Fig. 2 ). The thymus of p110δ E1020K-GL mice was normal 122 except for a mild reduction in single positive CD8 + T cells. In the spleens and lymph nodes 123 there were increased proportions of activated/memory T cells identified by high CD44 124
expression and low CD62L expression, and increased numbers of Foxp3 + T regulatory cells 125 ( Supplementary Fig 3) . These T cell and B cell phenotypes were recapitulated in p110δ E1020K Analysis of serum immunoglobulins showed that p110δ E1020K-GL mice had elevated levels of 132
IgG1 and IgG2b and a trend towards increased levels of IgG2c, IgA, and IgE isotypes 133 compared to wild-type mice. There was also a trend to hyper IgM in p110δ E1020K-GL mice as 134 is frequently observed in APDS patients 10, 11, 14 , whereas p110δ D910A mice were antibody 135 deficient ( Supplementary Fig 6) . The level of serum IgG3, which has been shown to be 136 protective against S. pneumoniae 19 , was comparable in p110δ E1020K-GL and wild-type mice 137
( Supplementary Fig 6) . 138 139
Susceptibility to S. pneumoniae is caused by PI3Kδ hyper-activation in B cells
140
Given that the immunological phenotype of p110δ E1020K-GL mice strongly resembled that of 141 APDS, we sought to determine whether these mice recapitulate the increased susceptibility 142 to S. pneumoniae observed in APDS patients. We infected p110δ E1020K-GL , p110δ D910A , and 143 p110δ WT mice with S. pneumoniae (TIGR4 serotype 4) and followed their survival for 10 days 144 ( Fig 3A) . Interestingly, despite being antibody-deficient, p110δ D910A mice did not show 145 increased susceptibility to S. pneumoniae. By contrast, p110δ E1020K-GL mice showed 146 accelerated disease onset and increased mortality ( Fig 3A) . 147 148
In order to determine the cell type responsible for increased susceptibility to S. 149 pneumoniae, we next infected the lineage-restricted p110δ E1020K-B , p110δ E1020K-T and 150 p110δ E1020K-M mice. Myeloid expression of p110δ E1020K had no effect on the course of S. 151 pneumoniae infection ( Fig 3B) , whereas expression of p110δ E1020K in T cells was protective 152 ( Fig 3C) . Only the p110δ E1020K-B mice replicated the increased susceptibility of the 153 p110δ E1020K-GL mice to S. pneumoniae ( Fig 3D) . Furthermore, transfer of p110δ E1020K-B bone 154 marrow into irradiated RAG2 -/recipients also conferred increased susceptibility to 155 infection, which was only partially rescued by co-transferring wild-type and p110δ E1020K-B 156 bone marrow at a 1:1 ratio ( Fig 3E) . The p110δ E1020K mutation was introduced conditionally into myeloid cells, T cells and B cells by crossing onto Lyz2 cre , Cd4 cre and Mb1 cre lines respectively. The myeloid conditional mutation did not affect survival following S. pneumoniae infection in p110δ E1020K-M mice (B), while T cell conditional p110δ hyper-activation lead to improved survival in p110δ E1020K-T mice (C). However, introducing the p110δ E1020K mutation specifically in B cells (p110δ E1020K-B mice) replicated the increased susceptibility to S. pneumoniae seen in p110δ E1020K-GL mice (D). E: Transfer of p110δ E1020K-B bone marrow into irradiated RAG2 -/recipients also conferred increased susceptibility to S. pneumoniae infection compared to recipients receiving wild-type bone marrow, and this phenotype was not fully rescued in a 50% BM chimera. F-G: Naïve PI3Kδ E1020K mice produce normal levels of anti-phosphorylcholine IgM and significantly higher levels of anti-PC IgG, while PI3Kδ D910A mice produce no natural antibody. (Data from 2 independent experiments combined. A: n=24; B: n=22; C: n=20; D: n=20; E: n=20; F-G: WT n=11; E1020K n=8 D901A n=9). In order to further investigate antibody-mediated protection in the context of PI3Kδ hyper-171 activation, we immunized mice with Pneumovax, a 23-valent polysaccharide vaccine 25 . 172
Following infection with S. pneumoniae, wild-type mice were completely protected by this 173 vaccination protocol, while p110δ E1020K-GL mice were only partially protected, to a level 174 similar to that in non-immunized wild-type mice. By contrast, p110δ D910A mice did not 175 benefit from vaccination ( Fig 4A, B) . Interestingly, p110δ E1020K-GL mice and wild-type mice 176 produced a similar antibody response, in contrast to p110δ D910A mice that showed no 177 response ( Fig 4C) . These data indicate that Pneumovax vaccination clearly protects against 178 S. pneumoniae, as shown in immunized wild-type mice. Despite this protection p110δ E1020K 179 mice remained significantly more susceptible to S. pneumoniae infection. Together, these 180
data suggest that B cells can affect susceptibility to S. pneumoniae by a mechanism that is at 181 least in part antibody-independent. 182 183
To determine more definitively whether B cells can be pathogenic in the context of S. 184
pneumoniae infection, we infected wild-type and Ighm tm1 (µMT) mice which lack mature B 185 cells 26 . Strikingly, Ighm tm1 mice showed reduced susceptibility to S. pneumoniae infection, 186 delaying disease onset from ~2 days in wild-type mice to ~5 days in Ighm tm1 mice ( Fig 5) . 187
Although survival in Ighm tm1 mice was increased up to 30 days post infection compared to 188 wild-type mice, CFU counts from the lungs of mice surviving to this time-point indicates 189 that, despite appearing clinically healthy, 41% (7/17) of Ighm tm1 mice failed to clear the 190 infection compared to 100% clearance in wild-type mice ( Fig 5) . Taken together, these 191 results suggest that during early time-points in the local infected environment B cells can be 192 pathogenic, while at later stages they are required to prevent chronic infection. 193 194
Increased susceptibility to S. pneumoniae could either be due to uncontrolled bacterial 195 proliferation or be caused by an aberrant immune response to the pathogen. The bacterial 196 titers from lungs and spleens of wild-type, p110δ D910A and p110δ E1020K-GL mice were similar 197 at 24h post infection, suggesting that the different susceptibilities did not correlate with 198 different abilities to control bacterial outgrowth during the early phase of infection 199
( Supplementary Fig 7A) . We observed a trend towards increased levels of TNFα, IL-6, IL-1β 200
and IL-1α in the lung tissue of p110δ E1020K-GL mice at 24h post infection ( Supplementary Fig  201  7B ). Consistent with this, the levels of TNFα, IL-6 and IL-1β were reduced in the lungs of 202 wild-type mice treated with nemiralisib prior to S. pneumoniae infection ( Supplementary Fig  203  7C ), indicating that, while PI3Kδ signaling affect the amount of pro-inflammatory cytokines 204 produced in response to infection, the increase in response to PI3Kδ hyper-activation is 205 modest. CD19 + B220 -B cells produce high levels of IL-10 in response to S. pneumoniae 208 infection in comparison with conventional CD19 + B220 + B cells 209 We hypothesized that increased susceptibility to S. pneumoniae infection can be mediated 210 by a specific subpopulation of B cells. Therefore, we studied the B cell compartment in 211 various tissues and found an atypical population of CD19 + B220 -B cells that was rare in wild-212 type mice, but significantly increased in p110δ E1020K-GL mice and was absent in p110δ D910A 213 mice ( Fig 6A) . In the spleen and bone marrow, there was a 10-and 5-fold increase, 214
respectively, in the numbers of CD19 + B220 -B cells in p110δ E1020K-GL mice compared to wild-215 type mice ( Fig 6A) . Infection with S. pneumoniae did not induce further expansion of 216 CD19 + B220 -B cells in the lungs or other tissues examined 24h post-infection ( Fig 6B) . 217 218 To ascertain if these cells were also present in the lungs and to distinguish resident from 219 circulating cells, we labelled circulating leukocytes in wild-type and p110δ E1020K-GL mice by 220
intravenous injection of biotin-conjugated anti-CD45. We then stained the lung homogenate 221
with fluorochrome-conjugated anti-mouse CD45 and streptavidin, and used flow cytometry 222
to distinguish tissue resident leukocytes from those present in the lung capillaries. We found 223 a significant increase in the proportion and number of tissue-resident, but not circulating, B 224 cells in p110δ E1020K-GL mice compared to wild-type mice. There was an increase in both 225 CD19 + B220 + and CD19 + B220cells among the tissue-resident B cells which demonstrates 226 that both populations can take residence in the lung ( Supplementary Fig 8) . 227 228
Given that B cells from p110δ E1020K-GL mice drive susceptibility to S. pneumoniae in an 229 antibody-independent manner, we sought to look at other properties of B cells. We found a 230 trend towards lower IL-10 protein levels and a significant 10-fold decrease in IL-10 mRNA 231 expression at 24h post infection in whole lung homogenates from wild-type mice treated 232 with nemiralisib ( Supplementary Fig 7C, D) , indicating that PI3Kδ signaling can regulate IL-10 233 levels in the lung post infection. IL-10 is an important immune-regulatory cytokine known to 234 affect the course of S. pneumoniae infection 27, 28 and therefore increased IL-10 production 235 could explain the B cell-dependent but antibody-independent effects seen in p110δ E1020K-GL 236 mice. To investigate this further, we crossed the p110δ E1020K-GL and p110δ D910A mice with a 237 highly sensitive IL-10 reporter (Il10 ITIB ) mouse 29 . 238 239
At 24h post S. pneumoniae infection, the frequencies of the IL-10-producing B cells were 240 significantly increased in the lungs of p110δ E1020K-GL Il10 ITIB mice compared to in wild-type 241
Il10 ITIB mice ( Supplementary Fig 7E) . In addition, IL-10-producing B cells were barely 242 detected in lungs from p110δ D910A mice ( Supplementary Fig 7E) . Frequencies of the IL-10-243
producing CD11b + myeloid, T and NK cells in lungs were variable, but not consistently 244 increased in p110δ E1020K-GL mice ( Supplementary Fig 7E) . Further analysis of the CD19 + B cell 245 subset isolated from lungs and spleens at 24h post S. pneumoniae infection showed that the 246 proportion of IL-10-producing cells was increased among the B220 -B cell subset as 247 compared to the B220 + B cell subset in p110δ E1020K-GL mice (5% B220 + vs 68% B220 -) and 248 wild-type mice (2% B220 + vs 55% B220 -) ( Fig 6C) . Furthermore, the proportion and absolute 249 number of IL-10-producing CD19 + B220cells and CD19 + B220 + cells was increased in 250 p110δ E1020K-GL mice compared to wild-type mice, while such IL-10-producing cells were 251 virtually absent in p110δ D910A mice ( Fig 6C) . This indicates that CD19 + B220cells are the 252 predominant population of B cells that produce IL-10 in a PI3Kδ-dependent manner. Previously, B cells that produce IL-10 have been termed B regulatory cells (Bregs) 30 . We 255 sought to compare the phenotype of CD19 + B220 -IL-10-producing B cells with conventional 256 IL-10-producing CD19 + B220 + Bregs described previously (Fig 7) . Following in vitro 257 stimulation for 5h and analysis of cell surface markers and intracellular IL-10 we found that 258 there were clear phenotypic differences between conventional B220 + Breg cells and the 259 B220 -B cells we describe here, including the differential expression of CD43 and IgM (Fig 7) . 260
The lack of B220 expression and low IgM expression differentiate the CD19 + B220 -IL-10-261 producing B cells from conventional B1 cells 31 . 262 263
Nemiralisib ameliorates the susceptibility to S. pneumoniae in p110δ E1020K mice 264 Given that increased PI3Kδ activity in mice leads to increased mortality after S. pneumoniae 265 infection we explored if nemiralisib would provide protection. Treatment of p110δ E1020K-GL 266 mice with inhaled nemiralisib 24h prior to infection led to a 20% increase in survival. While 267 nemiralisib treatment did not affect the numbers of CD19 + B220 -B cells, the proportion of IL-268 10 producing CD19 + B220 -B cells in the lungs were reduced in comparison to non-treated 269 mice ( Fig 8A) . This was in keeping with our prior observations that nemiralisib treatment 270 reduced IL-10 mRNA levels in the lung tissue of S. pneumoniae infected wild-type mice 271
( Supplementary Fig 7D) , suggesting a role for IL-10-producing CD19 + B220 -B cells in the 272
PI3Kδ-dependent susceptibility to infection.
274
Nemiralisib treatment suppresses IL-10 production in B cells of APDS patients 275 Cohort studies have shown that 75% of patients with APDS have elevated circulating 276 transitional B cells (CD19 + IgM ++ CD38 ++ ) 14 . Other studies have shown that such transitional B 277 cells can produce high levels of IL-10 32, 33 . We obtained blood samples from patients with 278 APDS and healthy controls and confirmed that all of these APDS patients had elevated 279
proportions of transitional B cells ( Fig 8B) . We isolated PBMCs from two of these APDS 280 patients and three healthy controls and stimulated them for 72h with anti-CD3 and IL-2 32 . 281
After stimulation we found more IL-10-producing B cells and more IL-10-producing 282 transitional B cells in PBMCs of APDS patients than in PBMCs of healthy controls, while 283 treatment with nemiralisib effectively suppressed IL-10 production in these cells ( Fig 8C) . 284
Therefore, in keeping with reduction of CD19 + B220 -IL-10 producing B cells in the mice, 285
nemiralisib can also reduce IL-10 producing human transitional B cells. In order to compare surface marker expression from B220and B220 + IL-10 producing B cells, splenocytes from Il10 ITIB mice (WT and E1020K) were stimulated with LPS/PdBu/Ionomycin/Brefeldin A for 5 hours and then stained for cell surface markers as shown. A: After gating on IL-10 producing B cells, CD43 ++ B220cells were compared to CD43 -B220 + cells. Histograms highlighting the differential surface marker expression as measured by median fluorescence intensity (MFI) between these populations are shown. B: Comparison of surface marker MFI show that CD19 + B220 -IL-10 + B cells express: CD43 ++ CD5 int/+ CD23 -CD21 -CD1d lo/int IgM +/-IgD lo/-PDL1 -CD138as opposed to conventional Bregs expressing: CD19 hi B220 hi IL-10 + CD43 -CD5 Var CD23 -CD21 ++ CD1d hi IgM hi IgD Var/lo PDL1 + CD138 int . ( affected by PI3Kδ activity and can also protect against immediate challenge is not known. 303
However, we did not detect increased proportions of Th17 cells after infection. Regardless 304 of the mechanism, the protection offered by T cells was overcome by the adverse effects of 305 B cells in p110δ E1020K-GL mice. 306 307
We describe a subset of B cells which lack the common B cell marker B220, and whose 308 abundance is correlated with the susceptibility to S. pneumoniae infection. Moreover, we 309
show that the development of this CD19 + B220 -B cell subset is highly dependent on the level 310 of activity of PI3Kδ. Susceptibility to S. pneumoniae infection was not altered in p110δ D910A 311 mice as compared to wild-type mice. Kinase-dead p110δ D910A mice lack natural and anti-312 capsular antibodies which may make them more susceptible, however, their lack of 313 CD19 + B220 -B cells may counterbalance this antibody deficiency, such that overall the 314 mutation has little net effect on S. pneumoniae susceptibility. 315 316
PI3Kδ signaling controls IL-10 production in B cells 317 A large proportion of the CD19 + B220 -B cells produced IL-10. Although increased IL-10 could 318 potentially reduce the production of inflammatory cytokines, we found similar or increased 319 levels of TNFα, IL-6 and IL-1 in the lungs of p110δ E1020K mice and no difference in CFU counts 320 at 24h post infection. 321 322
One of the defining characteristics of APDS patients is an increased proportion of 323 CD24 + CD38 + B cells defined as transitional B cells 10-12, 14, 15 . Intriguingly, production of IL-10 324 is a characteristic of these B cells as well. High IL-10 levels in response to secondary S. 325 pneumoniae infection following influenza A is associated with increased lethality when 326 compared to a primary S. pneumoniae infection, and importantly, the outcome of a 327 secondary S. pneumoniae infection is improved by IL-10 neutralisation 27, 28 . This indicates 328 that, while IL-10 is required for normal immune regulation and resolution of inflammation 35 , 329 excess IL-10 during the early stages of S. pneumoniae infection could have an acute 330 detrimental effect. This fits with our observation that nemiralisib treatment improved the 331 outcome of mice infected with S. pneumoniae and reduced IL-10 mRNA levels in the lung. 332 10 Further studies are required to investigate the time and location specific effects of B cell 333 dependent IL-10 production, keeping in mind that B cells have the potential to produce a 334 number of different cytokines (such as IL-6, TNF-, and IL-35) that could affect S. 335 pneumoniae susceptibility 36 . 336 337 We postulate that the transitional B cells which are expanded in APDS patients may not just 338 be precursors to more mature B cells, but also include cells that are functionally equivalent 339
to the CD19 + B220cells that we have identified in p110δ E1020K mice and thus may also 340 contribute to the increased susceptibility to S. pneumoniae infection and hence to the high 341 incidence of bronchiectasis characteristic of this disease 15 . In this context, it is interesting 342 that CD19 + B220 -B cells had previously been described as immature progenitors in the bone 343 marrow 37 , rather than a functional PI3Kδ dependent subset found in peripheral tissues as 344
we describe here. Although the CD19 + B220 -B cells we describe resemble B1 cells by some 345 criteria, such as the expression of CD5 and CD43, their lower IgM expression, lack of B220 346 and distribution pattern suggest that they are related but distinct to conventional B1 and 347 B10 cells 30, 31 . A similar subset has previously been described as being dependent on CD19 348
and increased in the absence of PTEN expression and PTEN haploinsuffiency in humans can 349 lead to an APDS-like syndrome 38 University College, London)) was grown to mid-log phase (OD500 = 0.5-0.7) in Todd-Hewitt 398 broth (Oxoid) supplemented with 0.5% yeast extract (Oxoid) at 37°C, 5% CO2. The bacteria 399
were collected by centrifugation, and resuspended in PBS/20% glycerol (Sigma-Aldrich) prior 400
to freezing in liquid N2 and storage at -80 °C. Stocks were assessed for viable CFU counts and 401 homogeneity by plating out serial dilutions of three frozen samples on blood agar plates (LB 402 agar, supplemented with 5% defibrinated sheep blood (Oxoid)) after incubation for 24h at 403 37 °C, 5% CO2. S. pneumoniae colonies were confirmed by the presence of an α-hemolytic 404 zone and sensitivity to optochin (Sigma-Aldrich). Virulent stocks were maintained by 405
performing an in vivo passage every 6-12 months. 406 407
S. pneumoniae infections 408
Frozen stocks were thawed and washed twice by centrifugation in sterile PBS before 409 resuspending at 4x10 7 CFU/mL in PBS. The suspension was kept on ice at all times, and used 410 for infection within 2h of thawing (no loss of viability was observed under these conditions). 411
Mice were lightly anaesthetized by inhalation of 3% isoflurane and maintained with 2% 412 isoflurane. Mice (males and females aged 8-12 weeks) were infected intranasally with 50µL 413 S. pneumoniae suspension containing 2x10 6 CFU. Animals were observed to confirm 414 inhalation of the dose and full recovery from anesthesia. The infection dose was routinely 415 confirmed by plating out serial dilutions of the inoculum on blood agar plates, as described 416 above. 417 418
Survival studies 419
Mice were infected with S. pneumoniae as described above. Pre-infection body weights 420
were recorded and animals were weighed daily post infection. Animals were monitored 421 three times a day for a period of 10 days post infection. Disease progression was assessed 422 by assigning clinical scores without knowledge of the individual genotypes: 0: Healthy; 1: 423 mild clinical signs; 2: Up to 2 moderate clinical signs; 3: up to 3 moderate signs. Animals 424 were culled when they showed >25% bodyweight loss or reach score 3. The most frequently 425 observed clinical signs were piloerection, hunched posture, tremor, and labored breathing. 426
At the study end-point, animals were culled and terminal blood samples collected. 427 428
Bone Marrow transfer 429
A single cell suspension of p110δ E1020K-B and wild-type (C57Bl/6.SJL) donor bone marrow was 430 prepared in sterile HBSS (Sigma-Aldrich) as described below (Isolation of immune cells from 431 mouse tissues). Cells from two sex-matched donors were pooled. RAG2 -/recipient mice 432
were supplied with 4mg/mL Neomycin (Sigma-Aldrich) in drinking water before sub-lethal 433 irradiation (one dose of 500Rads over 63 seconds), and received 3x10 6 donor cells by 434 intravenous (tail vein) injection. Neomycin treatment was maintained for 4 weeks post 435 transfer, and after 8 weeks reconstitution was confirmed by analyzing tail bleeds. 436 437
Vaccination 438
For vaccine studies, mice were immunized with Pneumovax II (pneumococcal 439 polysaccharide vaccine, serotypes: Blood samples were taken from the tail vein prior to vaccination and 14 days after 444 vaccination into serum collection tubes (BD microtainer, SST) samples were centrifuged at 445 15000xg for 5 min and the serum stored at -20°C until analysis. 446 447
Nemiralisib treatment 448
The PI3Kδ inhibitor nemiralisib (GSK2269557) was supplied by GSK, Respiratory Refractory 449
Inflammation DPU, UK. The nemiralisib suspension was prepared on the day of use in 0.2% 450
Tween80, and administered intranasally to mice twice daily at 0.2mg/kg in a total volume of 451 50µL, as described above (S. pneumoniae infections). Unless otherwise specified, the first 452 dose was given 24h before infection, and treatment was maintained for the duration of the 453 study. 454 455
Isolation of immune cells from mouse tissues 456
Mice were euthanized by CO2 inhalation and cervical dislocation. Lungs were perfused with 457 10mL cold PBS through the right ventricle, and collected into cold PBS. Lungs were 458 homogenized using a GentleMACS tissue dissociator and mouse lung dissociation enzyme kit 459
from Miltenyi according to the manufacter's instructions. The homogenate was transferred 460 to 15mL tubes (BD Falcon) and washed by centrifugation (500xg) in 10mL cold PBS. The 461 pellet was resuspended in 3mL 37.5% isotonic Percoll (Sigma) at room temperature and 462 centrifuged at 650xg for 20min with low acceleration and no brake. The supernatant 463
including tissue debris was removed, and the cell pellet was washed and resuspended in 464 cold PBS. Where CFU counts were required, the right lung was processed as described 465 above and the left lung was processed for CFU counts as described below. Bone marrow 466 cells were collected by flushing cold PBS through femurs and tibias collected, filtered 467 through 40µm cell strainers and washed by centrifugation in 5mL PBS. Spleens, thymus and 468 peripheral lymph nodes were homogenized in PBS by pushing the tissue through 40µm cell 469 strainers (BD) using a syringe plunge. The cell suspension was then transferred to a 15ml 470
Tube (BD falcon) and washed once in 5ml cold PBS. For blood, bone marrow and spleen, red 471 blood cells (RBC) were lysed using hypotonic ammonium chloride RBC lysis buffer (Sigma). 472
Lysing was quenched with cold PBS and the cells were collected by centrifugation. Single 473 cell suspensions were processed for flow cytometry as described below. 474 475 14
S. pneumoniae CFU counts 476
Lungs were homogenized in 1ml PBS using a Bullet Blender using 3x 3mm steel beads: speed 477 8, 3min (Next Advance, USA). Spleens were homogenized as described above in 2mL PBS. 478
Serial dilutions (10-fold) were performed for spleen and lung homogenates, and samples 479 were plated out on blood agar as described above. Plates were incubated for 24h at 37°C 480 and S. pneumoniae colonies were counted. 481 482
In vitro stimulation of mouse B cells 483
Splenocytes were isolated from naïve wild-type, p110δ E1020K-GL and p110δ D910A mice that had 484 been crossed with the Il10 ITIB reporter line as described above and the total cell count was 485 obtained using a CASY counter. The cells were resuspended in complete RPMI (RPMI plus 486 5% (v/v) FCS, 50 μM β-mercaptoethanol and 100 μg/ml penicillin and streptomycin) and 487 plated at 5x10 6 cells in 100µL per well in a 96-well U bottom plate. The cells were stimulated 488 with 10 ng/ml LPS, 50ng/ml PdBu (Sigma, USA), 0.25 μg/ml Ionomycin (Sigma, USA) and 1 489 μl/ml of Brefeldin A (eBioscience) for 5h at 37 °C. The cells were then processed for IL-10 490 detection and flow cytometry as described below. 491 492
Detection of IL-10 in Il10 ITIB reporter mice: 493
Single cell suspensions from S. pneumoniae infected mice or in vitro stimulated cells were 494 prepared as described above. The cells were incubated with 3.3µM CCF4-AM, a 495
Fluorescence Resonance Energy Transfer substrate for β-lactamase (LiveBLAzer kit, 496
Invitrogen), and 3.6mM probenecid (Sigma) in complete RPMI for 90min at 29°C, as 497 previously described 29 , then placed on ice and collected by centrifugation. Cells were then 498 processed for flow cytometry as described below. 499 500
Flow cytometry 501
Antibodies used for flow cytometry are listed in Table 1 . Single cell suspensions were 502 stained using an antibody master mix in PBS/0.5%BSA for 40min at 4°C. Cells were washed 503 and fixed in 4% paraformaldehyde (Biolegend) for 10min at room temperature before 504 washing 2x in PBS/0.5%BSA. For intracellular detection of IL-10 in human samples, the cells 505
were fixed and permeabilized with Cytofix/Cytoperm buffer (BD Biocsiences, USA) following 506 surface staining. For FoxP3 staining, the eBioscence FoxP3/Transcription Factor staining 507
Buffer Set was used according to the manufacturer's instructions. Non-fluorescent counting 508 beads (AccuCount Blank Particles 5.3µm; Spherotech, USA) were added to quantify absolute 509 cells numbers. Samples were kept at 4°C until analysis (BD Fortessa5). Analysis was carried 510 out using FlowJo (Treestar) analysis software. 511 512
In vitro stimulation of human B cells 513
Freshly isolated PBMCs from patients and control individuals were stimulated with 0.5μg/ml 514 purified plate bound anti CD3 monoclonal antibody (clone-OKT3) (Invitrogen) and 20ng/ml 515 recombinant human IL2 in presence or absence of, the p110δ inhibitor, nemiralisib (10nM) 516 for 72h. This stimulation led to the activation of CD40L (CD154) on CD4 T cells. The 517
interaction between CD40L on CD4 T cells with CD40 on B cells resulted in the production of 518 IL-10 in regulatory B cells. For a final stimulation 50ng/ml PdBu (sigma, USA), 0.25 μg/ml 519 ionomycin (Sigma, USA) and 1μl/ml of Brefeldin A (eBioscience) were also added for the last 520 4h. Cells were washed, surface stained, fixed and permeabilized with Cytofix/Cytoperm 521 buffer (BD Biocsiences, USA) for the intracellular detection of IL-10 as described above. 522 15 523
Natural Antibody ELISA 524
Anti-phosphorylcholine IgM and IgG levels were assessed in serum from naïve mice. Blood 525 samples were collected by cardiac puncture and serum collected as described above. NUNC 526
Maxisorp ELISA plates were coated overnight at 4°C with 20µg/mL phosphorylcholine-BSA 527 (BioSearch) in sodium bicarbonate coating buffer (pH9) (Biolegend) (100µL/well). Plates 528
were washed 4x with PBS/0.2% Tween20 followed by blocking for 1h at room temperature 529 in PBS/1%BSA. Serum samples were diluted 1:10 in PBS/1% BSA and pooled WT serum was 530 diluted from 1:5 to 1:400 to confirm the linear range of the assay. After removing the 531 blocking solution, samples were added at 100µL/well, and the plates were incubated 532 overnight at 4°C. The plates were then washed 4x in PBS/0.2%Tween20. Polyclonal HRP 533 conjugated goat-anti-mouse IgM (abcam ab97023) or IgG (abcam ab97230) was diluted 534 1:5000 in PBS/1% BSA, added at 100µL per well and the plates were incubated for 2h at 535 room temperature. The plates were washed 6x with PBS/0.2%Tween20, TMB substrate 536 (Biolegend) was added at 100µL per well and incubated for 5-10 min at room temperature. 537
The reaction was stopped by adding 50µL 2N H2SO4 solution. Absorbance was read at 538 450nm (Fluostar omega, BMG Labtech). 539 540
Tissue resident cell analysis (lung) 541
Mice received an intravenous (tail vein) injection of 3µg anti-mouse CD45 conjugated to 542 biotin (Biolegend, clone 30-F11) in 100µL PBS. 4min after injection animals were killed and 543 the lungs were collected into cold PBS without prior perfusion. Lungs were then finely 544 minced using a scalpel blade and the pushed through a 100µm cell strainer (BD) the 545 homogenate was collected in a 15mL tube (BD falcon) and washed in 10ml cold PBS. The 546 pellet was resuspended in 3mL 37.5% isotonic Percoll (Sigma) at room temperature and 547 processed as described above. The cells were stained for flow cytometry as described 548
above, including streptavidin APC to identify anti-CD45-Biotin labelled circulating cells. 549 550
Cytokine analysis 551
Cytokine levels were measured in the supernatant from lung homogenates prepared for 552 CFU analysis. The homogenates were centrifuged for 1min at 10000xg to remove tissue 553 debris. Samples collected from wild-type mice treated with nemiralisib were analyzed using 554
Meso Scale Discovery mouse Th1/Th2 9-plex ultrasensitive kits, according to manufacturer's 555 instructions. Samples collected from genetically modified mice were analyzed using the flow 556 cytometry based Legendplex mouse inflammation 13-plex panel (Biolegend). 557 558
Gene Array 559
Wild-type mice were treated with nemiralisib and infected with S. pneumoniae as described 560
above. At 24h post infection, whole lungs were collected and snap frozen in liquid nitrogen. 561
Samples were randomized and analyzed (Affymetrix Genechip Mouse genome 430 2.0 562 Array) by Expression Analysis, Quintiles Global Laboratories. Data analysis was performed by 563
Computational Biology and Statistics, Target Sciences, GlaxoSmithKline, Stevenage. Data 564 was normalised using the robust multiarray average method 47 and quality checked in 565 R/Bioconductor 48 using the affy package 49 . A linear model was fitted to the RMA 566 normalised data for each probset and differiential expression analysis was conducted in the 567
ArrayStudio software (Omicsoft Corporation). P-values were false discovery rate corrected 568 by the method of Benjamini and Hochberg 50 . Probes with an absolute fold change >1.5 and 569 an adjusted p-value <0.05 were called significant. The data been deposited in the National 570
Center for Biotechnology Information Gene Expression Omnibus (GEO) and are accessible 571 through GEO series accession number GSE109941. 572 573
Luminex antibody analysis 574
Measurement of IgG recognizing pneumococcal polysaccharide of 13 serotypes was 575 performed as described previously 51 . The assay was modified in order to measure murine 576
IgG as follows: 50µl of 1:10 diluted mouse sera was added to each well containing the 577 pneumococcal polysaccharides coupled to microspheres and the secondary antibody used 578 was 50µl of 10µg/ml goat F(ab')2 anti-mouse IgG (H+L)-R-phycoerythrin (Leinco 579
Technologies, Inc). R-PE fluorescence levels were recorded for each serotype and median 580 fluorescence intensities were compared for the different genotypes. 581 582
PIP3 quantification 583
CD4 and CD8 cells were isolated from mouse splenocytes using immunomagnetic negative 584 selection by biotinylated cocktail of antibodies and Streptavidin dynabeads (Invitrogen). T 585 cells were stimulated with anti-CD3 (1mg/ml), (145-2c11, Biolegend) anti-CD28 (2µg/ml), 586
(35.51, Biolegend) antibodies followed by crosslinking with anti-Armenian hamster IgG (10 587 µg/ml, Jackson ImmunoResearch labs). Cells were stimulated for 1 min at 37°C. B cells were 588 similarly isolated from mouse splenocytes and stimulated for 1 min at 37 °C with anti-IgM 589 2µg/ml (AffinPure F(ab')2 Fragment goat anti-mouse IgM from Jackson Immuno-Research 590 labs). 591 592
After stimulation of the cells, we terminated the reactions by addition of 750µl kill solution 593
(CHCl3:MeOH:1M HCL (10:20:1) and immediately froze the samples on dry ice. PIP3 levels 594
were quantified by mass spectrometry as previously described 52 . 595 596
Western blot 597
Purified T and B cells were isolated from murine spleens and stimulated as described above 598 (PIP3 measurement). For performing western blots the stimulation period was 5 min. 599
Isolated T cells were stimulated with anti -CD3 1µg/ml and anti -CD28 (2 µg/ml) with or 600 without 10 Nm nemiralisb; or B cells with anti-IgM 4µg/ml (AffinPure F(ab')2 Fragment goat 601 anti-mouse IgM from Jackson ImmunosResearch labs). 602
Stimulated T and B cells were lysed with ice-cold lysis buffer (50mM HEPES, 150mM NaCl, 10mM 603 NaF, 10mM Indoacetamide, 1% IGEPAL and proteinase inhibitors (Complete Ultra tablets, Roche)) for 604 15-20 min. Lysates were centrifuged at 15,000g for 10 min at 4 °C and supernatants were 605 mixed with NuPage LDS sample buffer (life technologies). Samples were heated at 70°C and 606 resolved on 4-12% NuPage bis-tris gel (Invitrogen), transferred to PVDF membranes and 607 probed with the following antibodies: pAKT (T308, Cell Signaling, 1 in 1000 dilution); total 608 AKT1 (2H10, Cell signaling, 1 in 2000 dilution); p110δ (Sc7176, Santa Cruz Biotechnology, 1 609 in 200 dilution); pS6 (S235/236, Cell Signaling, 1 in 500 dilution); pFoxo1/3a (T24/T32, Cell 610
Signaling, 1 in 1000 dilution); pErk (p44/42, Cell Signaling, 1 in 200 dilution); βActin 611 (Sc47778, Santa Cruz Biotechnology, 1 in 2000 dilution). 612
Statistics 613
Data analysis was performed in Graphpad Prism. Where two groups were compared we 614 used student's t-test with Welch's correction. Where three or more groups were compared 615 we used 1-way ANOVA with Tukey's multiple comparisons test. Survival data was analyzed 616 using the Gehan-Breslow-Wilcoxon test. Statistical significance is indicated by asterisk as 617 follows: p > 0.05 *; p ≤ 0.05 **; p ≤ 0.01 ***; p ≤ 0.001 **** 618
Animal experiments were performed according to the Animals (Scientific Procedures) Act 620 1986, licence PPL 70/7661. 621
Informed consent was obtained from patients and healthy controls. This study conformed to 622 the Declaration of Helsinki and according local ethical review document 12/WA/0148. 623 
Supplementary Figure 1: Gene targeting strategy for generating conditional p110δ E1020K mice
The p110δ E1020K mice were generated by OzGene using homologous recombination in ES cells. A duplicate sequence corresponding to the last coding exon in Pik3cd was flanked by loxP sites and inserted 3' to the original sequence. The original sequence encoding E1020 was mutated to K1020. Upon Cre-mediated recombination, the wild-type sequence is replaced by the mutant E1020K sequence. In this study, we used Tnfrsf4 cre to delete in the germline, Cd4 cre to delete in T cells, Mb1 cre to delete in B cells and Lyz2 Cre to delete in myeloid cells. Analysis of serum immunoglobulins from naïve mice (age 8-12 weeks) showed significantly increased levels of IgG1 and IgG2b, and a trend towards increased levels IgG2c, IgM, IgA, and IgE in p110δ E1020K-GL mice, while IgG3 levels were similar compared to wild-type mice. p110δ D910A mice were antibody deficient for all isotypes analyzed. (n= 6-7). A: 24h post S. pneumoniae infection, lung and spleen CFU counts were similar in wild-type, p110δ E1020K-GL and p110δ D910A mice. B: 24h post infection, cytokine levels in the lung homogenate showed a trend towards increased TNFα, IL-6 and IL-1 in p110δ E1020K mice. C: 24h prophylactic treatment with nemiralisib (nem) led to a significant reduction in TNFα, IL-6 and IL-1β, and a trend towards reduced IFNγ and IL-10, in the lungs of wild-type mice compared to vehicle control (veh) treated animals at 24h post infection. D: Volcano plot (statistical significance against fold change) of the gene expression changes in response to nemiralisib treatment showed reduced levels of proinflammatory cytokines as well as IL-10 at 24h post infection compared to vehicle control treatment. All genes analysed are shown (grey dots) with the cytokines of interest labelled and coloured; green for those with a negative fold change, red for positive fold change. E: Analysis of immune cell subsets in Il10 ITIB reporter mice at 24h post infection showed that the proportion of IL-10 producing B cells is significantly increased in p110δ E1020K-GL mice and reduced in p110δ D190A mice compared to wild-type mice, with similar trends in T cells and myeloid cells not reaching significance. (A: results from 2 independent studies combined, n=14; B: representative data from 3 independent studies n=8; C: Combined data from 4 independent experiments n=25; D: data from 1 study, n=6; E: representative data from 2 independent studies n=6). p=0.0117 0 2 10 2 4 10 2 6 10 2 8 10 2 1 10 3 p=0.0044 Supplementary Figure 8 : Tissue resident B cell numbers are increased in the lungs of naïve p110δ E1020K-GL mice Biotin-conjugated anti-CD45 was injected intravenously to distinguish between circulating (CC) and tissue resident (TRC) cells in the lungs of naïve mice. p110δ E1020K-GL mice showed an increase in the proportion and number of tissue resident leukocytes (CD45 + TRC), but not circulating leukocytes. There was also an increase in the proportion and number of total CD19 + B cells among the tissue resident cell population. Among circulating leukocytes (CD45 + IV), total CD19 + B cell numbers were similar in p110δ WT and p110δ E1020K mice, and p110δ E1020K mice had increased numbers and proportions of CD19 + B220 -B cells. (Representative data from 2 independent experiments n=4). 
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